| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
EC50: 3 nM (Smo)[1]
|
|---|---|
| ln Vitro |
With an EC50 of 3 nM, SAG (0.1 nM-100 μM; 30 h) stimulates firefly luciferase expression in Shh-LIGHT2 cells, which is subsequently inhibited at higher concentrations[1]. When SAG (1-1000 nM; 1 h) competes with BODIPY-cyclopamine to bind to Smo-expressing Cos-1 cells, the SAG/Smo complex has an apparent dissociation constant (Kd) of 59 nM[1]. Robotnikinin-induced pathway activation by ShhN is inhibited by SAG (100 nM)[2]. In MDAMB231 cells, SAG (250 nM; 48 h) dramatically raises SMO mRNA and protein expression[3]. In MDAMB231 cells, SAG (250 nM; 24 and 48 hours) boosts the expression of CAXII mRNA at 24 hours under both normoxic and hypoxic conditions[3]. MDAMB231 cell migration is increased by SAG (250 nM; 24 h)[3].
|
| ln Vivo |
In CD-1 mice, SAG (1.0 mM) causes a notable rise in BV/TV at the eight-week timepoint and increased osteogenesis, primarily at the defect borders[4]. In mice, SAG (15–20 mg/kg; ip) dose-dependently causes pre-axial polydactyly to occur[5].
|
| Animal Protocol |
Animal/Disease Models: Pregnant C57BL/6J mice[5]
Doses: 15, 17, 20 mg/kg Route of Administration: A single ip Experimental Results: Effective in ca. 80% of the embryos and increased Gli1 and Gli2 mRNA expression in the limb bud, with Gli1 mRNA being the most upregulated at the dose of 20 mg/kg. |
| References |
[1]. Chen JK, et al. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6.
[2]. Stanton BZ, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009 Mar;5(3):154-6. [3]. Guerrini G, et, al. Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration. J Cell Physiol. 2018 Dec; 233(12): 9799-9811. [4]. Lee S, et al. Combining Smoothened Agonist (SAG) and NEL-like protein-1 (NELL-1) Enhances Bone Healing. Plast Reconstr Surg. 2017 Feb 13. [5]. Fish EW, et al. Preaxial polydactyly following early gestational exposure to the smoothened agonist, SAG, in C57BL/6J mice. Birth Defects Res A Clin Mol Teratol. 2016 Nov 1. |
| Molecular Formula |
C28H30CL3N3OS
|
|---|---|
| Molecular Weight |
562.98
|
| CAS # |
2702366-44-5
|
| Related CAS # |
SAG;912545-86-9;SAG hydrochloride;2095432-58-7;(Rac)-SAG;364590-63-6
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (177.63 mM)
DMSO: 33.33 mg/mL (59.20 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (88.81 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7763 mL | 8.8813 mL | 17.7626 mL | |
| 5 mM | 0.3553 mL | 1.7763 mL | 3.5525 mL | |
| 10 mM | 0.1776 mL | 0.8881 mL | 1.7763 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
